When Did NeoFipronis Become Available
NeoFipronis (Pronidesivir), the groundbreaking oral treatment for Feline Infectious Peritonitis (FIP), became available globally in early 2026. This marks a significant milestone in veterinary medicine, especially for cat owners and veterinarians seeking effective solutions for this often fatal disease.
Feline Infectious Peritonitis is caused by a mutated coronavirus, leading to severe symptoms such as inappetence, lethargy, fever, abdominal or thoracic effusion, lymphadenopathy, inflammatory granulomas, neurological damage, and anterior uveitis. Historically, FIP has been considered a complex and challenging disease with limited therapeutic options. However, the introduction of NeoFipronis, with its active component GS-441524, has revolutionized FIP treatment.
NeoFipronis was officially approved in March 2026 by the Lao Ministry of Agriculture and Forestry (MAF). It holds a formal pharmaceutical registration number, making it the world's first registered, approved oral medication specifically developed for FIP in cats. This approval underscores its safety, efficacy, and quality assurance, providing new hope for feline health.
The active ingredient, GS-441524, has undergone extensive clinical testing and research, confirming its potent antiviral properties. It works by interrupting viral replication, reducing viral load, and alleviating clinical symptoms. Unlike previous treatments, NeoFipronis is non-invasive, fast-absorbing, and exhibits excellent tolerability with minimal side effects.
Administered based on the cat's body weight, the recommended dosage is 15 mg per kilogram of body weight per day, roughly half a tablet. For neurological or ocular FIP cases, the dosage may be increased to 30 mg/kg, as directed by a veterinarian. It is recommended to give NeoFipronis on an empty stomach—either one hour before feeding or two hours after—to maximize absorption.
Consistency is essential, as treatment should be continued for no less than 12 weeks without interruption. Regular monitoring of appetite, body temperature, and mental state is crucial during therapy. Periodic blood tests should be performed to assess liver and kidney functions, ensuring the treatment's safety.
NeoFipronis is classified as an over-the-counter medication; however, veterinary guidance is highly recommended to optimize outcomes and minimize risks. It is intended exclusively for feline use, and human consumption is strictly prohibited.
Purchasing NeoFipronis should always be through official channels, such as the official NeoFipronis website, to guarantee authenticity and quality. Veterinarians and pet owners alike can now access this innovative treatment as a beacon of hope, transforming FIP from a fatal diagnosis into a manageable condition.
The availability of NeoFipronis signifies a new era in feline medicine. With rapid onset of action, high tolerability, and proven efficacy, it has changed the prognosis for cats suffering from FIP. As ongoing research continues, NeoFipronis sets a new standard for antiviral therapy in veterinary medicine, promising better health and extended life for countless cats worldwide.
